Skip to content

DaHuang GangTsao Tang to Improve the Appetite Loss Condition of Cancer Patients

Taking Herbal Formula:DaHuang GangTsao Tang to Improve the Appetite Loss Condition of Cancer Patients in Late-stage:A Clinical Control Trial Study

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01503346
Acronym
TCM
Enrollment
4
Registered
2012-01-04
Start date
2011-03-31
Completion date
2013-03-31
Last updated
2020-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-organic Loss of Appetite

Keywords

Appetite Loss

Brief summary

Appetite loss is a severe and common symptom among late-stage cancer patients, and it causes great the anxiety for the patient's family. In TCM theory, the investigators call these patients are in block and repulsion condition. The investigators try to set a study to use the herbal medicine solution taken in frequent small amounts by cancer patients in late-stage to improve the appetite loss condition. Through this method, the investigators not only want to improve the quality of life of cancer patients in late-stage but also set a valuable treatment.

Detailed description

Intervention group * 1\. 2 grams of DaHuang abstract powder and 0.5 grams GanTsao abstract powder are mixed and separated into four packages; * 2\. each package was given to each patient four times a day (three time after meal and one time before sleep); * 3\. each patient received the usual medication of the hospice ward at the same time; * 4\. record the patients' score of pre-test, mid-test and after-test of QIPCTP at the 1st day, the 3rd day and the 6th day; * 5\. record the patients' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative Oncology Group Performance Status) at the 1st day and the 6th day. Control group * 1\. each patient received the usual medication of the hospice ward during the trial interval; * 2\. record the patients' score of receive pre-test, mid-test and after-test of QIPCTP at the 1st day, the 3rd day and the 6th day; * 3\. record the patients' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative Oncology Group Performance Status) at at the 1st day and the 6th day. Medicine DaHuang herbal abstract powder is produced by Sun Ten Pharmaceutical Co., Ltd, and it's product serial number: 276001. GanCao herbal abstract powder is also produced by Sun Ten Pharmaceutical Co., Ltd, and it's product serial number: 185645. Each herbal abstract powder is qualified with the data of HPLC to confirm each content and stability. The pharmaceutical company is qualified by Good Manufacturing Practice (GMP) certification in Taiwan.

Interventions

DRUGDaHuang GanTsao Tang

Intervention group 1. 2 grams of DaHuang abstract powder and 0.5 grams GanTsao abstract powder are mixed and separated into four packages; 2. each package was given to each patient four times a day (three time after meal and one time before sleep); 3. each patient received the usual medication of the hospice ward at the same time; 4. record the patients' score of pre-test, mid-test and after-test of QIPCTP at the 1st day, the 3rd day and the 6th day; 5. record the patients' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative Oncology Group Performance Status) at the 1st day and the 6th day.

Sponsors

Changhua Christian Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Terminal cancer patients in hospice ward * Patients with appetite loss condition * Ages between 20 to 80 years old * No history of diabetes

Exclusion criteria

* Entered the stage of dying patients * Receiving other traditional Chinese medicine

Design outcomes

Primary

MeasureTime frameDescription
appetite score6 daysThe investigators detect the patients' appetite condition at the 1st,3rd and 6th day.

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026